New ASCO Survivorship Guidelines Acknowledge Successes Against Cancer

The American Society of Clinical Oncology has issued a trio of new clinical guidelines for issues that cancer survivors often must deal with, signaling a measure of success in the war against cancer.

The new guidelines confront three problems for survivors, with varying degrees of success: fatigue, depression, and peripheral neuropathy. They are the first of a planned 18 clinical practice guidelines that the ASCO intends to issue in the coming months.

In a statement, ASCO officials said,

The recommendations reinforce the need to care for both the physical and psychological needs of cancer survivors. The release of these guidelines come at a time when the number of people with a history of cancer in the US has increased dramatically, from 3 million in 1971 to about 13.7 million today. Despite these important gains, cancer survivors still face a range of long-term challenges from their disease and its treatment. Cancer survivors face an increased risk for other health problems, premature morbidity, and side effects from treatment.

In developing guidelines for anxiety and depression, the ASCO panel simply adapted the recommendations made by the Pan-Canadian Practice Guidelines on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults with Cancer (those Canadian guidelines can be seen at this link, which opens as a PDF file).

In developing guidelines for fatigue, the ASCO panel found no evidence that supported the use of drug therapy like using psychostumulants; rather, the evidence supported non-drug interventions such as exercise, yoga, acupuncture, and social activity.

Neuropathy poses problems

The problematic guideline was for peripheral neuropathy. This panel could find no good evidence supporting the use of any treatment that was aimed at prevention or management of the development of peripheral neuropathy, and in fact they noted several drugs that should not be used to prevent chemotherapy-induced neuropathy, including ALC, amitripyline, calcium, glutathione, and vitamin E, among others.

In all, they concluded that the only recommended treatment for chemo-induced peripheral neuropathy is duloxetine.

To underscore the difficulty in this area, Gary Lyman, M.D., from Fred Hutchinson Cancer Center and acting chair of the ASCO Survivorship Guidelines Advisory Committee, said in a statement, "There is no clear panacea for neuropathy ... Some of the drugs used for prevention or treatment of neuropathy may cause side effects or interfere with other drugs."

To view the guidelines in their entirety, visit this page at the ASCO website.

Photo credit: NCI

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap